X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Nebivolol is a beta blocker with two special features: it acts particularly selectively on the heart (high beta-1 selectivity) and it also widens the blood vessels through the messenger nitric oxide. That is where its reputation as the better tolerated beta blocker comes from. This article sorts out what is plausible about that claim, what is genuinely proven, and which typical beta blocker issues remain all the same.
See more detail.gif)
Most of the relevant interactions come down to one question: what else slows heart rate and conduction? A second group concerns the breakdown through CYP2D6.
| Combination | Consequence | What to do |
|---|---|---|
| Calcium channel blockers of the verapamil or diltiazem type | Heart rate and conduction can fall to dangerous levels | Usually avoided, otherwise only under close monitoring |
| Antiarrhythmics (e.g. amiodarone, flecainide) and digoxin | Pulse and conduction are slowed even further | Pulse and ECG checks |
| Insulin and sulfonylureas such as glimepiride | The warning signs of a hypo are blunted | Measure more often (section 9) |
| NSAIDs such as ibuprofen or diclofenac | The blood-pressure-lowering effect is weakened | Only short term and after checking with your doctor |
| CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, bupropion) | Nebivolol levels rise, more fatigue | Declare the combination, a lower dose may be needed |
| Anaesthetics and alcohol | A stronger fall in blood pressure, more dizziness | Mention it before procedures, see medications before surgery |
The first point is the most important one: a beta blocker and a heart-acting calcium channel blocker slow the same system at two different places. Together they can push the pulse down far enough to cause dizziness, fainting or heart block. Check new combinations in the guide to drug interactions; on the subject of alcohol, medications and alcohol is worth reading.
All three are beta-1 selective beta blockers used for similar conditions. The differences lie in the detail — and they matter more in practice than the shared substance class suggests.
| Active substance | Special feature | Typical uses | Practically relevant |
|---|---|---|---|
| Nebivolol | The highest beta-1 selectivity, plus NO-mediated widening of the vessels | High blood pressure; heart failure in older people | A reputation for better tolerability; the evidence for superiority is limited; breakdown depends on CYP2D6 |
| Metoprolol | Fat-soluble, enters the brain more readily; available as a slow-release and an immediate-release form | Coronary heart disease, after a heart attack, heart failure, migraine prevention | The broadest evidence base; dreams and sleep problems somewhat more common |
| Bisoprolol | High beta-1 selectivity, long duration of action, not very fat-soluble | Heart failure, coronary heart disease, high blood pressure | Very well documented in heart failure; reliable 24-hour cover |
Where it is about proven effectiveness in heart failure or after a heart attack, metoprolol and bisoprolol have the thicker file of trials. Where it is about tolerability for someone who cannot cope with other beta blockers, nebivolol is a sensible candidate. Switching within the group is possible, but it is not a matter for self-medication — the strengths cannot be converted one to one.
This is the practical point that the patient information leaflet covers too briefly. The early warning signs of a hypo — trembling, a pounding heart, inner restlessness — do not come from the low blood sugar itself but from the adrenaline response to it. And that is exactly what a beta blocker dampens. The result: a hypo arrives more quietly. It is not necessarily more frequent, but it is noticed later.
That does not mean beta blockers are forbidden in diabetes — after a heart attack or in heart failure they are often particularly important. It means: measure more often while things are being changed, and make sure the people around you know that the warning signs have shifted.
If you do any sport, you notice a beta blocker immediately: your pulse no longer climbs as high under exertion as it used to. The rule of thumb “220 minus your age” produces a number on nebivolol that simply no longer applies.
The NO effect is occasionally cited as an argument that performance suffers less than on other beta blockers — plausible, but not proven for everyday life. Regular exercise lowers blood pressure on top of the medication: lowering blood pressure naturally and medications and exercise.
If treatment is to be ended or changed, it is done by tapering: the dose is reduced step by step over one to two weeks, and longer in coronary heart disease — background in the guide stopping medications. The most common reason for an unplanned stop is a banal one: the pack runs out. Order repeat prescriptions in good time and take enough with you when you travel (see medications when travelling).
Here lies the most important honest point: even a highly selective beta blocker is not risk-free in obstructive airway disease. Selectivity depends on the dose; at higher doses beta-2 receptors are blocked as well, and the narrowing of the airways can then get worse. In addition, the effect of reliever inhalers such as salbutamol can be weakened.
In asthma, a beta blocker is traditionally regarded as a contraindication, or as usable only after particularly careful weighing up.¹ In COPD the assessment is more nuanced: where there is a compelling indication, cardioselective beta blockers are as a rule considered acceptable, because the benefit for the heart outweighs the risk. Report new shortness of breath or a rising need for your reliever inhaler promptly.
In older people with chronic heart failure, nebivolol has a place of its own — it is licensed for this group and has been studied in a large trial in people over 70.³ At the same time, the risk of too slow a pulse and of falls rises with age, which is why treatment is started lower. With impaired kidney function a lower starting dose usually applies; with markedly impaired liver function nebivolol is, according to the Summary of Product Characteristics, not suitable — see medications in old age and medications with kidney and liver disease.
Not necessarily. Part of the fatigue on any beta blocker comes from the fact that the pulse can no longer rise under exertion — and that effect is intended. Two things are still worth a look: first the dose, because in slow CYP2D6 metabolisers even 5 mg can act like a high dose; second the time of day you take it. The fatigue often improves markedly after four to six weeks.
No, this is a known subject and one to be taken seriously. Beta blockers are among the groups for which erection problems are reported — partly through the effect itself, partly through expectation. For nebivolol there are indications of a more favourable profile; large-scale evidence is lacking. What matters is this: say something. A dose adjustment, a switch or targeted treatment are all possible — quietly stopping the tablet is the worst option. An overview is in the guide erectile dysfunction pills compared.
A low resting pulse is to be expected on a beta blocker and is not in itself an alarm signal, as long as you feel well and can cope with exertion. It becomes critical when symptoms come with it: dizziness, a drop in stamina, a feeling of faintness, or a pulse that barely rises even under exertion. Note your readings over several days — a record says more at your appointment than a single number. If your fingers turn white in attacks and hurt, the article cold hands and feet helps with making sense of it.
The interaction check shows critical combinations before you take them.
